跳至主要内容

Custom Synthesis

MuseChem engages in total-support business for research and development of organic compounds for the chemical, pharmaceutical and agrochemical industries. We provide custom manufacturing and process research services on scales ranging from milligrams to kilograms. MuseChem’s scientists in the chemistry team are well trained, can handle even the most complex chemical synthesis and characterization projects, completing the project on your required timeframe.
Your inquiry will be evaluated within a few days to provide you with a quote complemented by a synthetic scheme. The quote is calculated on the basis of the current FTE rate. We deliver detailed biweekly reports with expected delivery dates. Each project is treated under the confidentiality agreement. We won't charge our clients for failed syntheses.
We offer high-quality and cost-effective custom synthesis service under strict confidentiality including the following:
● Small-Scale and large scale manufacturing
● Process development of cost effective processes
● Scale-up of existing literatures or customer supplied syntheses, custom manufacturing of chemicals in bulk quantities
We look forward to providing you with the best possible answers and will strive to respond to your email inquiry as quickly as possible.

评论

发表评论

此博客中的热门博文

A major introduction to T-705!

Favipiravir (cas 259793-96-9 ), also known as T-705 or Avigan, is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. It is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5'-triphosphate (RTP). Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options.
1 条评论
阅读全文

A major introduction to K03861!

Kinases can switch between active and inactive conformations of the ATP/Mg(2+) binding motif DFG, which has been explored for the development of type I or type II inhibitors. However, factors modulating DFG conformations remain poorly understood. We chose CDK2 as a model system to study the DFG in-out transition on a target that was thought to have an inaccessible DFG-out conformation. We used site-directed mutagenesis of key residues identified in structural comparisons in conjunction with biochemical and biophysical characterization of the generated mutants. As a result, we identified key residues that facilitate the DFG-out movement, facilitating binding of type II inhibitors. However, surprisingly, we also found that wild type CDK2 is able to bind type II inhibitors. Using protein crystallography structural analysis of the CDK2 complex with an aminopyrimidine-phenyl urea inhibitor ( K03861 ) revealed a canonical type II binding mode and the first available type II inhibitor CDK2 co
发表评论
阅读全文

Itacitinib is in stock now!

Itacitinib(cas# 1334298-90-6) , also known as INCB39110 or INCB039110, is a potent JAK1 tyrosine kinase inhibitor, which is currently in Phase II trials for the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis. INCB039110 produced significant improvements in sPGA, demonstrating proof of concept in chronic plaque psoriasis.
发表评论
阅读全文